摘要
目的观察靶剂量培哚普利联合美托洛尔治疗扩张型心肌病(DCM)合并心衰的临床疗效。方法 28例患者在常规治疗的基础上分别加用培哚普利2～8(5.4±1.8)mg/d,服药13～37(17.1±3.5)个月;美托洛尔12.5～200(124.2±35.3)mg/d;1 a后复查6min步行试验、超声心动图和动态心电图与治疗前对比。结果 DCM患者心衰症状改善明显,NYHA分级由治疗前Ⅳ级8例、Ⅲ级16例、Ⅱ级4例改善为Ⅳ级1例、Ⅲ级5例、Ⅱ级19例、Ⅰ级3例;心排指数(CI)由(1.86±0.63)L/m2升至(2.81±0.79)L/m2;左室射血分数(LVEF)由(31.42±7.08)%上升到(41.76±8.27)%;SDNN、rMSSD分别由(67.35±18.24)ms、(19.46±5.23)ms上升到(91.62±24.51)ms、(26.81±7.26)ms;6 min步行试验由(116.4±67.2)m上升到(437.5±71.5)m;且患者无明显不良反应。结论靶剂量的培哚普利联合美托洛尔对DCM合并心衰患者疗效好,可有效控制DCM患者心衰的发作,提高生活质量。
Objective It is to observe the clinical curative effect of target dosage Perindopril combined with metoprolol on dilated cardiomyopathy（DCM） combined with heart failure.Methods 28 patients were treated with conventional therapy added with Perindopril 2～8（5.4±1.8） mg/d for 13～37（17.1±3.5） months and metoprolol 12.5～200（124.2±35.3） mg/d.The 6-Minute-Walking Test,echocardiogram and Holter monitoring electrocardiogram after 1 year were rechecked and contrasted with that before treatment.Results The heart failure symptoms of DCM patients were improved obviously.The NYHA level before treatment were level Ⅳ 8 cases,levelⅢ 16 cases and levelⅡ 4 cases and those after treatment were level Ⅳ 1 case,level Ⅲ 5 cases,levelⅡ 19 cases and level Ⅰ 3cases.The CI was improved from（1.86±0.63） L/m2 to（2.81±0.79） L/m2.The LVEF was improved from（31.42±7.08）% to（41.76±8.27）%.The SDNN was improved from（67.35±18.24） ms to（91.62±24.51） ms.The rMSSD was improved from（19.46±5.23） ms to（26.81±7.26） ms.The results of 6-minute walk test was improved from（116.4±67.2） m to（437.5±71.5） m.Besides,there was no obvious untoward reaction.Conclusion Target dosage Perindopril combined with metoprolol has good curative effect on DCM combined with heart failure patients,and which can effectively control the attack of heart failure in DCM patients and heighten the life quality.
出处
《现代中西医结合杂志》
CAS
2010年第29期3695-3697,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
